Multiple Cancers(多种癌症)研究综述
Multiple Cancers 多种癌症 - BACKGROUND Tumor mutational burden (TMB) is an important independent biomarker for the response to immunotherapy in multiple cancers. [1] The therapeutic value of CD133 is a biomarker of the CSC in multiple cancers. [2] Supplemental Digital Content is available in the text Valid estimates of cancer treatment costs are import for priority setting, but few studies have examined costs of multiple cancers in the same setting. [3] The gene fusion of Neurotrophic tropomyosin receptor kinase (NTRK) promotes the formation of tumors and is closely related to multiple cancers. [4] Background Long noncoding RNA single nucleotide polymorphisms (lncRNA-SNPs) PCAT1 rs710886, PRNCR1 rs1456315 and CCAT2 rs6983267 on 8q24 region present generalizability in the susceptibility to multiple cancers, however, the influence of rs710886, rs1456315 and rs6983267 on lung cancer has not been assessed. [5] It is critical to identify decisive genes involved in the development and progression of cancer, and joint analysis of multiple cancers may help to discover overlapping mechanisms among different cancers. [6] Consistent with these results, human TCGA analyses reveal a strong positive correlation between type 17 and CD8+ T cell exhaustion signature gene sets in multiple cancers. [7] Studies have demonstrated that children exposed to febrile infectious diseases show a subsequent reduced risk for ovarian cancer, melanoma and many other cancers, while common acute infections in adults are associated with reduced risks for melanoma, glioma, meningioma and multiple cancers. [8] Some of the unique characteristics commonly encountered in HCRC cases include early age of onset, synchronous/metachronous cancer occurrence, and multiple cancers in other organs. [9] Treatment with immune checkpoint inhibitors (ICIs) has considerably improved prognosis in multiple cancers. [10] lncRNAs can be genes modulators to affect the biological process of multiple cancers. [11] c‐Jun activation domain‐binding protein‐1 (Jab1) is aberrantly overexpressed in multiple cancers and plays an oncogenic role in cancer progression. [12] Background: Myosin heavy chain 9 (MYH9) plays essential role in human diseases including multiple cancers, however, little is known about the mechanism of MYH9 in gliomas. [13] NDRG1 is an oncogenic signaling disruptor that plays a key role in multiple cancers, including aggressive pancreatic tumors. [14] Administration of MCJ mimetics in combination with standard chemotherapeutic drugs could therefore become an alternative strategy for treatment of multiple cancers. [15] The use of immune checkpoint inhibitors (iCPI) in the treatment of multiple cancers has gained prominence due to their high efficacy. [16] Serine/Arginine-Rich Splicing Factor 7 (SRSF7), which is previously recognized as a splicing factor, has been revealed to play oncogenic roles in multiple cancers. [17] Anomalous expression of micro RNAs (miRNAs) and circular RNAs (circRNAs) were strongly correlated to the progression of multiple cancers, including multiple myeloma (MM). [18] The TME subtypes correlate with patient response to immunotherapy in multiple cancers, with patients possessing immune-favorable TME subtypes benefiting the most from immunotherapy. [19] The RNA editing enzyme ADAR, is an attractive therapeutic target for multiple cancers. [20] Protein arginine methyltransferase 6 (PRMT6) catalyzes monomethylation and asymmetric dimethylation of arginine residues in various proteins, plays important roles in biological processes, and is associated with multiple cancers. [21] Kaposi sarcoma-associated herpesvirus (KSHV) is the causative agent of multiple cancers in immunocompromised patients including two lymphoproliferative disorders associated with KSHV infection of B lymphocytes. [22] Immune checkpoint blockade (ICB) has demonstrated efficacy in multiple cancers, offering the potential of long-term disease control not achievable with cytotoxic or targeted therapies. [23] This locus contains the PVT1 gene, which encodes a long noncoding RNA (lncRNA) that has been implicated in multiple cancers including BC. [24] The constitutive photomorphogenic 1 (RFWD2), referred to an E3 ubiquitin ligase, has been identified as an oncogene in multiple cancers, yet important questions on the role of RFWD2 in MM biology and treatment remain unclear. [25] N6-methyladenosine (m6A) modification is an important regulatory factor affecting diseases, including multiple cancers and it is a developing direction for targeted disease therapy. [26] Immune-related lncRNA signatures predicting prognosis have been reported in multiple cancers, but relevant studies in gastric cancer (GC) are still lacking. [27] The main objectives of this study were to visualize the prognostic landscape of SLC1A5 in multiple cancers and determine the relations between SLC1A5 expression and tumor immunity. [28] Conclusions These results indicated a role for SLC7A7 in infiltration of CD8 + T cells, CD4 + T cells, tumor-associated macrophages (TAMs), neutrophils and DCs in multiple cancers, and regulation of T cell exhaustion and Tregs in NSCLC. [29] PLOD family proteins are strongly linked to multiple cancers, and PLOD1 is recognized as a prognostic marker of gastric carcinoma. [30] Low-frequency mutations in multiple cancers perturbing 1624 ceM have been verified by Student’s t-test, indicating a significant mechanism of changes in the expression level of oncogenic genes. [31] SIGNIFICANCE: Although immune-checkpoint inhibitors are approved as dual checkpoint strategies, and in combination with cytotoxic chemotherapy and angiogenesis inhibitors for multiple cancers, patient benefit remains limited. [32] Here we discuss the known relationships between ETS proteins and enzymes that determine their ubiquitin status, their integration with other developmental signal transduction pathways and how suppression of ETS protein ubiquitination contributes to the malignant cell phenotype in multiple cancers. [33] While AIB1 is associated with the initiation and progression of multiple cancers, the mechanism by which AIB1 contributes to PDAC progression remains largely unknown. [34] Protein tyrosine kinase 7 (PTK7) plays an important role in multiple cancers. [35] MicroRNAs (miRNAs) were recently implicated in modifying the transforming growth factor β (TGF-β) signaling in multiple cancers. [36] We have refined the several subtypes from multiple cancers towards more molecularly coherent patient subgroups. [37] Our finding may be clinically useful in designing therapeutic strategies, prognosis assessment, and follow-up management in patients receiving immunotherapy in multiple cancers. [38] We propose that copper chelating agents, already in clinical trial for multiple cancers, may simultaneously target these mechanisms across a wide variety of cancers, serving as an excellent candidate for targeted combination therapy. [39] Background Long noncoding RNA (lncRNA), urothelial carcinoma-associated 1 (UCA1) is aberrantly expressed in multiple cancers and has been verified as an oncogene. [40] BACKGROUND The modified Glasgow Prognostic Score (mGPS), a clinical tool that incorporates albumin and C-reactive protein, has proven useful in the prognostication of multiple cancers. [41] Although emerging evidence has highlighted the importance of long noncoding RNAs in multiple cancers, the specific regulatory roles mostly remain obscure. [42] First, we explored the expression levels of RIPK2 in multiple cancers, including GC, using a bioinformatics approach. [43] It is also found to be an oncogene in multiple cancers and a potential target for tumor therapy. [44] BACKGROUND Circular RNAs (circRNAs) play crucial roles in multiple cancers, including colorectal cancer (CRC). [45] Moreover, macrophage‐derived extracellular vesicles (EVs) are involved in pathogenesis of multiple cancers, yet the functions of molecular determinants in which have not been fully understood. [46] In multiple cancers TIGIT is expressed on tumor-infiltrating cytotoxic T cells, helper T cells, regulatory T cells and NK cells, and its main ligand CD155 is expressed on tumor-infiltrating myeloid cells and upregulated on cancer cells, which contributes to local suppression of immune-surveillance. [47] These SNPs were selected based on their association with multiple cancers in literature. [48] Results DNASE1L3 was downregulated in multiple cancers, including breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD). [49] Curaxins and especially the second-generation derivative curaxin CBL0137 have important antitumor activities in multiple cancers such as glioblastoma, melanoma and others. [50]背景肿瘤突变负荷（TMB）是多种癌症免疫治疗反应的重要独立生物标志物。 [1] CD133 的治疗价值是多种癌症中 CSC 的生物标志物。 [2] 文本中提供了补充数字内容 癌症治疗成本的有效估计对于优先设置很重要，但很少有研究检查同一环境中多种癌症的成本。 [3] 神经营养原肌球蛋白受体激酶（NTRK）的基因融合促进肿瘤的形成，与多种癌症密切相关。 [4] 背景 长非编码 RNA 单核苷酸多态性 (lncRNA-SNPs) PCAT1 rs710886、PRNCR1 rs1456315 和 CCAT2 rs6983267 在 8q24 区域呈现出对多种癌症易感性的普遍性，然而，尚未评估 rs710886、rs1456315 和 rs6983267 对肺癌的影响。 [5] 确定参与癌症发展和进展的决定性基因至关重要，对多种癌症的联合分析可能有助于发现不同癌症之间的重叠机制。 [6] 与这些结果一致，人类 TCGA 分析揭示了多种癌症中 17 型和 CD8+ T 细胞耗竭特征基因组之间的强正相关。 [7] 研究表明，接触发热性传染病的儿童随后患卵巢癌、黑色素瘤和许多其他癌症的风险降低，而成人常见的急性感染与黑色素瘤、神经胶质瘤、脑膜瘤和多种癌症的风险降低有关。 [8] HCRC 病例中常见的一些独特特征包括发病年龄早、癌症同步/异时发生以及其他器官的多发性癌症。 [9] 免疫检查点抑制剂 (ICI) 治疗已显着改善多种癌症的预后。 [10] lncRNA 可以成为影响多种癌症生物学过程的基因调节剂。 [11] c-Jun 激活结构域结合蛋白-1 (Jab1) 在多种癌症中异常过表达，并在癌症进展中发挥致癌作用。 [12] 背景：肌球蛋白重链9（MYH9）在包括多种癌症在内的人类疾病中发挥着重要作用，然而，关于MYH9在胶质瘤中的作用机制知之甚少。 [13] NDRG1 是一种致癌信号干扰物，在多种癌症中发挥关键作用，包括侵袭性胰腺肿瘤。 [14] 因此，MCJ 模拟物与标准化疗药物联合给药可能成为治疗多种癌症的替代策略。 [15] 免疫检查点抑制剂 (iCPI) 在治疗多种癌症中的应用因其高效而备受关注。 [16] 此前被认为是一种剪接因子的富含丝氨酸/精氨酸的剪接因子 7 (SRSF7) 已被发现在多种癌症中发挥致癌作用。 [17] 微小 RNA (miRNA) 和环状 RNA (circRNA) 的异常表达与包括多发性骨髓瘤 (MM) 在内的多种癌症的进展密切相关。 [18] TME 亚型与患者对多种癌症免疫治疗的反应相关，具有免疫有利的 TME 亚型的患者从免疫治疗中获益最多。 [19] RNA 编辑酶 ADAR 是多种癌症的有吸引力的治疗靶点。 [20] 蛋白质精氨酸甲基转移酶 6 (PRMT6) 催化各种蛋白质中精氨酸残基的单甲基化和不对称二甲基化，在生物学过程中发挥重要作用，并与多种癌症相关。 [21] 卡波西肉瘤相关疱疹病毒 (KSHV) 是免疫功能低下患者多种癌症的病原体，包括与 B 淋巴细胞 KSHV 感染相关的两种淋巴组织增生性疾病。 [22] 免疫检查点阻断 (ICB) 已在多种癌症中显示出疗效，提供了细胞毒性或靶向治疗无法实现的长期疾病控制潜力。 [23] 该基因座包含 PVT1 基因，该基因编码一种长链非编码 RNA (lncRNA)，该基因与包括 BC 在内的多种癌症有关。 [24] 组成型光形态发生 1 (RFWD2)，称为 E3 泛素连接酶，已被确定为多种癌症中的致癌基因，但关于 RFWD2 在 MM 生物学和治疗中的作用的重要问题仍不清楚。 [25] N6-甲基腺苷（m6A）修饰是影响疾病包括多种癌症的重要调节因子，是靶向疾病治疗的发展方向。 [26] 在多种癌症中已经报道了预测预后的免疫相关 lncRNA 特征，但仍然缺乏对胃癌 (GC) 的相关研究。 [27] 本研究的主要目的是可视化 SLC1A5 在多种癌症中的预后情况，并确定 SLC1A5 表达与肿瘤免疫之间的关系。 [28] 结论 这些结果表明 SLC7A7 在多种癌症中浸润 CD8 + T 细胞、CD4 + T 细胞、肿瘤相关巨噬细胞 (TAM)、中性粒细胞和 DC，以及调节 NSCLC 中的 T 细胞耗竭和 Treg 中的作用。 [29] PLOD 家族蛋白与多种癌症密切相关，PLOD1 被认为是胃癌的预后标志物。 [30] 干扰 1624 ceM 的多种癌症中的低频突变已通过学生 t 检验得到验证，表明致癌基因表达水平变化的重要机制。 [31] 意义：虽然免疫检查点抑制剂被批准作为双重检查点策略，并与细胞毒性化疗和血管生成抑制剂联合用于多种癌症，但患者的益处仍然有限。 [32] 在这里，我们讨论了 ETS 蛋白和确定其泛素状态的酶之间的已知关系、它们与其他发育信号转导途径的整合以及 ETS 蛋白泛素化的抑制如何导致多种癌症中的恶性细胞表型。 [33] 虽然 AIB1 与多种癌症的发生和进展有关，但 AIB1 促进 PDAC 进展的机制仍然很大程度上未知。 [34] 蛋白酪氨酸激酶 7 (PTK7) 在多种癌症中发挥重要作用。 [35] 最近，MicroRNAs (miRNAs) 与改变多种癌症中的转化生长因子 β (TGF-β) 信号传导有关。 [36] 我们已经将多种癌症的几种亚型细化为分子上更一致的患者亚组。 [37] 我们的发现可能在临床上对接受多种癌症免疫治疗的患者设计治疗策略、预后评估和随访管理有用。 [38] 我们建议铜螯合剂已经在多种癌症的临床试验中，可以同时针对多种癌症的这些机制，作为靶向联合治疗的优秀候选者。 [39] 背景 长链非编码 RNA (lncRNA)、尿路上皮癌相关 1 (UCA1) 在多种癌症中异常表达，并已被证实为致癌基因。 [40] 背景 改良的格拉斯哥预后评分 (mGPS) 是一种结合了白蛋白和 C 反应蛋白的临床工具，已被证明可用于多种癌症的预后。 [41] 尽管新出现的证据强调了长链非编码 RNA 在多种癌症中的重要性，但具体的调控作用大多仍不清楚。 [42] 首先，我们使用生物信息学方法探索了 RIPK2 在包括 GC 在内的多种癌症中的表达水平。 [43] 它还被发现是多种癌症中的致癌基因，也是肿瘤治疗的潜在靶点。 [44] 背景 环状 RNA (circRNA) 在包括结直肠癌 (CRC) 在内的多种癌症中发挥着至关重要的作用。 [45] 此外，巨噬细胞衍生的细胞外囊泡（EVs）参与多种癌症的发病机制，但其分子决定因素的功能尚未完全了解。 [46] 在多种癌症中，TIGIT 在肿瘤浸润性细胞毒性 T 细胞、辅助性 T 细胞、调节性 T 细胞和 NK 细胞上表达，其主要配体 CD155 在肿瘤浸润性骨髓细胞上表达并在癌细胞上上调，有助于局部抑制免疫监视。 [47] 这些 SNP 的选择是基于它们与文献中的多种癌症的关联。 [48] 结果 DNASE1L3在多种癌症中下调，包括乳腺癌浸润癌（BRCA）、胆管癌（CHOL）、肝细胞癌（LIHC）和肺腺癌（LUAD）。 [49] Curaxins，尤其是第二代衍生物curaxin CBL0137在胶质母细胞瘤、黑色素瘤等多种癌症中具有重要的抗肿瘤活性。 [50]
long non coding
Long non-coding RNAs (lncRNAs) have been validated to play significant roles in biological process of multiple cancers. [1] Long non-coding RNA (LncRNA) HOTAIR has been considered as a pro-oncogene in multiple cancers, but its precise mechanism of tumor angiogenesis has rarely been reported. [2] BACKGROUND Long non-coding RNA (lncRNA) small nucleolar RNA host gene 15 (SNHG15) has been discovered and demonstrated to have significant function in multiple cancers. [3] Long non-coding RNA (LncRNA) BRAF-activated non-coding RNA (BANCR) has been shown to participate in many biological behaviors of multiple cancers. [4] BACKGROUND Long non-coding RNAs (lncRNAs) are involved in the occurrence and progression of multiple cancers, including non-small cell lung cancer (NSCLC). [5] Long non-coding RNA colorectal neoplasia differentially expressed (LncRNA CRNDE) was recognized as a significant oncogene in multiple cancers. [6] Substantial long non-coding RNAs (lncRNAs) were illustrated to have crucial roles in multiple cancers. [7] Abnormal expression of genes and long non-coding RNAs (lncRNAs) are reportedly linked to multiple cancers. [8] ABSTRACT Long non-coding RNA breast cancer antiestrogen resistance 4 (lncRNA BCAR4) is an independent factor on the survival prognosis of patients with multiple cancers. [9] Long non-coding RNA (lncRNA) 91 H has been reported to participated in multiple cancers. [10] ABSTRACT In recent years, FGD5 antisense RNA 1 (FGD5-AS1) was confirmed to be the long non-coding RNAs (lncRNAs) that could accelerate the development of multiple cancers. [11] Background Long non-coding RNAs (lncRNAs) are vital regulators of gene expression and cellular processes in multiple cancers, including melanoma. [12] BACKGROUND Long non-coding RNAs (lncRNAs) have been identified in multiple cancers. [13] PVT1 is a long non-coding RNA transcribed from a gene located at the 8q24 chromosomal region that has been implicated in multiple cancers including breast cancer (BC). [14] Background Hypoxia-related long non-coding RNAs (lncRNAs) have been proven to play a role in multiple cancers and can serve as prognostic markers. [15] Long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) is oncogenic in multiple cancers. [16] Accumulating studies have suggested that long non-coding RNAs (lncRNAs) play critical parts in multiple cancers. [17] Background Targeting the long non-coding RNAs (LncRNAs)-microRNAs (miRNAs)-mRNA competing endogenous RNA (ceRNA) networks has been proved as an effective strategy to treat multiple cancers, including oral squamous cell carcinoma (OSCC). [18] Long non-coding RNAs (lncRNAs) emerge as vital modulators and tissue-specific biomarkers of multiple cancers, including gastric cancer (GC). [19] Long non-coding RNA (lncRNA)-X-inactive-specific transcript (XIST) has been reported to be positively associated with multiple cancers. [20] Long non-coding RNA LINC00657 has a critical role in multiple cancers. [21] Long non-coding RNAs (LncRNAs) are reported to be upregulated or downregulated in multiple cancers and play a crucial role in the metastasis of tumors or prognosis. [22] Long non-coding RNA (lncRNA) FGD5 antisense RNA 1 (FGD5-AS1) was reported to exert critical roles in multiple cancers. [23] NEAT1 (nuclear paraspeckle assembly transcript 1) is an oncogenic long non-coding RNA (lncRNA) that facilitates tumorigenesis in multiple cancers. [24] Background In multiple cancers, long non-coding RNA small nucleolar RNA host gene 20 (lncRNA SNHG20) is generally dysregulated. [25]长链非编码 RNA (lncRNA) 已被证实在多种癌症的生物学过程中发挥重要作用。 [1] 长链非编码 RNA (LncRNA) HOTAIR 已被认为是多种癌症中的原癌基因，但其肿瘤血管生成的确切机制却鲜有报道。 [2] nan [3] nan [4] nan [5] nan [6] nan [7] nan [8] nan [9] nan [10] nan [11] nan [12] nan [13] nan [14] nan [15] nan [16] nan [17] nan [18] nan [19] nan [20] nan [21] nan [22] nan [23] nan [24] nan [25]
non small cell
Since alterations in FGFRs are common in multiple cancers, including breast cancer, non-small cell lung cancer and endometrial cancer, several kinase inhibitors targeting FGFRs are in clinical development. [1] Activated Cdc42-associated kinase 1 (ACK1) is an oncogene in multiple cancers, but the underlying mechanisms of its oncogenic role remain unclear in non-small cell lung cancer (NSCLC). [2] Immune checkpoint inhibition (ICI) via anti-PD-1/PD-L1 and anti-CTLA4, has improved clinical outcomes for multiple cancers, including non-small cell lung cancer (NSCLC), kidney cancer, and melanoma. [3] Pembrolizumab is a selective anti-PD-L1 humanised monoclonal antibody approved by the Food and Drug Administration for treating multiple cancers, including cervical cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, bladder cancer, and squamous head and neck cancer. [4] Hsa_circ_0001947 is associated with multiple cancers, but its function in non-small cell lung cancer (NSCLC) is ambiguous and needs further research. [5] BACKGROUND Activating RET fusions are oncogenic drivers in multiple cancers and are identified in 1-2 % of non-small cell lung cancers (NSCLC). [6] GAS41 is an emerging oncogene overexpressed and implicated in multiple cancers, including non-small cell lung cancer (NSCLC). [7]由于 FGFRs 的改变在多种癌症中很常见，包括乳腺癌、非小细胞肺癌和子宫内膜癌，因此几种靶向 FGFRs 的激酶抑制剂正在临床开发中。 [1] 活化的 Cdc42 相关激酶 1 (ACK1) 是多种癌症中的致癌基因，但其致癌作用的潜在机制在非小细胞肺癌 (NSCLC) 中仍不清楚。 [2] nan [3] Pembrolizumab 是美国食品药品监督管理局批准的选择性抗 PD-L1 人源化单克隆抗体，用于治疗多种癌症，包括宫颈癌、非小细胞肺癌 (NSCLC)、肾细胞癌、膀胱癌和鳞状头颈癌癌症。 [4] nan [5] nan [6] nan [7]
programmed cell death
Immunotherapy targeting either programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently shown a curative effect on multiple cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma. [1] Antibodies against checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) and its ligand anti-programmed death ligand 1 (PD-L1) have shown clinical efficacy in the treatment of multiple cancers. [2] Immune checkpoint inhibitors directed at the programmed cell death protein 1 pathway (PD1), including nivolumab and durvalumab, have been approved for the treatment of multiple cancers. [3] Ferroptosis, a novel iron-dependent programmed cell death, is involved in the development of multiple cancers. [4] BACKGROUND Immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) inhibitors, are used to treat multiple cancers. [5]靶向程序性细胞死亡蛋白 1 (PD-1) 或程序性死亡配体 1 (PD-L1) 的免疫疗法最近显示出对多种癌症的疗效，包括黑色素瘤、非小细胞肺癌和肾细胞癌。 [1] 针对检查点抑制剂的抗体，如抗程序性细胞死亡蛋白 1 (PD-1) 及其配体抗程序性死亡配体 1 (PD-L1) 已显示出治疗多种癌症的临床疗效。 [2] nan [3] nan [4] nan [5]
squamous cell carcinoma
Results: We found that the mRNA expression of SHOX2 was higher in multiple cancers, including LUAD and lung squamous cell carcinoma (LUSC), than in normal tissues. [1] Aberrant expression or mutation of the Septin gene family is closely associated with cancer progression, and septin 2 (SEPT2) exerts its tumor‐promoting effects in multiple cancers, but its role in regulating laryngeal squamous cell carcinoma (LSCC) progression and drug resistance has not been investigated. [2] Although accumulating evidence demonstrates that TDO2 overexpression is implicated in the development and progression of multiple cancers, its tumor-promoting role in esophageal squamous cell carcinoma (ESCC) remains unclear. [3] Socioeconomic status (SES) is associated with diagnostic and treatment delays and survival in multiple cancers, but less data exist for anal squamous cell carcinoma (ASCC). [4]结果：我们发现 SHOX2 的 mRNA 表达在多种癌症中高于正常组织，包括 LUAD 和肺鳞状细胞癌 (LUSC)。 [1] Septin基因家族的异常表达或突变与癌症进展密切相关，septin 2（SEPT2）在多种癌症中发挥促肿瘤作用，但其在调节喉鳞状细胞癌（LSCC）进展和耐药性方面的作用尚未被调查。 [2] nan [3] nan [4]
intergenic non protein
As reported previously, long intergenic non-protein coding RNA 284 (LINC00284) is an important regulator in multiple cancers. [1] BACKGROUND LINC00152 (long intergenic non-protein coding RNA 152) was identified as an oncogenic lncRNA in multiple cancers. [2] Long intergenic non-protein coding RNA 858 (LINC00858) has been identified to participate in multiple cancers. [3]如前所述，长基因间非蛋白编码 RNA 284 (LINC00284) 是多种癌症中的重要调节因子。 [1] 背景 LINC00152（长基因间非蛋白质编码 RNA 152）被鉴定为多种癌症中的致癌 lncRNA。 [2] nan [3]